- Home
- YSXT vs SKYE Comparison
YSXT vs SKYE Comparison
Compare YSXT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSXT
- SKYE
- Stock Information
- Founded
- YSXT 2011
- SKYE 2012
- Country
- YSXT China
- SKYE United States
- Employees
- YSXT N/A
- SKYE N/A
- Industry
- YSXT Automotive Aftermarket
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- YSXT Consumer Discretionary
- SKYE Health Care
- Exchange
- YSXT Nasdaq
- SKYE Nasdaq
- Market Cap
- YSXT 127.7M
- SKYE 73.4M
- IPO Year
- YSXT 2024
- SKYE N/A
- Fundamental
- Price
- YSXT $5.45
- SKYE $4.52
- Analyst Decision
- YSXT
- SKYE Buy
- Analyst Count
- YSXT 0
- SKYE 6
- Target Price
- YSXT N/A
- SKYE $16.60
- AVG Volume (30 Days)
- YSXT 371.8K
- SKYE 2.0M
- Earning Date
- YSXT 08-15-2025
- SKYE 08-08-2025
- Dividend Yield
- YSXT N/A
- SKYE N/A
- EPS Growth
- YSXT N/A
- SKYE N/A
- EPS
- YSXT 0.18
- SKYE N/A
- Revenue
- YSXT $66,143,276.00
- SKYE N/A
- Revenue This Year
- YSXT N/A
- SKYE N/A
- Revenue Next Year
- YSXT N/A
- SKYE N/A
- P/E Ratio
- YSXT $29.71
- SKYE N/A
- Revenue Growth
- YSXT 21.23
- SKYE N/A
- 52 Week Low
- YSXT $2.06
- SKYE $1.14
- 52 Week High
- YSXT $9.96
- SKYE $7.60
- Technical
- Relative Strength Index (RSI)
- YSXT N/A
- SKYE 74.70
- Support Level
- YSXT N/A
- SKYE $3.41
- Resistance Level
- YSXT N/A
- SKYE $5.75
- Average True Range (ATR)
- YSXT 0.00
- SKYE 0.60
- MACD
- YSXT 0.00
- SKYE 0.17
- Stochastic Oscillator
- YSXT 0.00
- SKYE 69.27
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.